Paper41008338
Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?
Rossini E and 4 others. Brain Sci, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now? Papers, record 41008338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41008338
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References170
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24373505 | A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. | J Autoimmun | 2014 | https://conductscience.org/library/papers/24373505 | PubMed |
| 2 | 38751755 | Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study. | Ther Adv Neurol Disord | 2024 | https://conductscience.org/library/papers/38751755 | PubMed |
| 3 | 39987373 | Myasthenia gravis in 2025: five new things and four hopes for the future. | J Neurol | 2025 | https://conductscience.org/library/papers/39987373 | PubMed |
| 4 | 32526271 | Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. | Clin Immunol | 2020 | https://conductscience.org/library/papers/32526271 | PubMed |
| 5 | 23341732 | New treatments for myasthenia: a focus on antisense oligonucleotides. | Drug Des Devel Ther | 2013 | https://conductscience.org/library/papers/23341732 | PubMed |
| 6 | 27220659 | International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. | Muscle Nerve | 2016 | https://conductscience.org/library/papers/27220659 | PubMed |
| 7 | 12360217 | Unravelling the pathogenesis of myasthenia gravis. | Nat Rev Immunol | 2002 | https://conductscience.org/library/papers/12360217 | PubMed |
| 8 | 38436998 | Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial. | JAMA Neurol | 2024 | https://conductscience.org/library/papers/38436998 | PubMed |
| 9 | 35639288 | Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. | Drugs | 2022 | https://conductscience.org/library/papers/35639288 | PubMed |
| 10 | 37564637 | Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. | Front Immunol | 2023 | https://conductscience.org/library/papers/37564637 | PubMed |
| 11 | 33662696 | Low-dose rituximab treatment for new-onset generalized myasthenia gravis. | J Neuroimmunol | 2021 | https://conductscience.org/library/papers/33662696 | PubMed |
| 12 | 37388903 | Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction. | SAGE Open Med | 2023 | https://conductscience.org/library/papers/37388903 | PubMed |
| 13 | 35243555 | Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis. | J Neurol | 2022 | https://conductscience.org/library/papers/35243555 | PubMed |
| 14 | 39624955 | Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis. | Eur J Neurol | 2025 | https://conductscience.org/library/papers/39624955 | PubMed |
| 15 | 31594658 | Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers. | J Autoimmun | 2020 | https://conductscience.org/library/papers/31594658 | PubMed |
| 16 | 25745635 | Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. | Neurol Neuroimmunol Neuroinflamm | 2015 | https://conductscience.org/library/papers/25745635 | PubMed |
| 17 | 38152089 | Guideline for the management of myasthenic syndromes. | Ther Adv Neurol Disord | 2023 | https://conductscience.org/library/papers/38152089 | PubMed |
| 18 | 37996128 | CAR T cells for treating autoimmune diseases. | RMD Open | 2023 | https://conductscience.org/library/papers/37996128 | PubMed |
| 19 | 38711503 | B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis. | Front Immunol | 2024 | https://conductscience.org/library/papers/38711503 | PubMed |
| 20 | 15848049 | Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. | J Autoimmun | 2005 | https://conductscience.org/library/papers/15848049 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42776983 | Identification of rs28362336 as a risk SNP for generalized myasthenia gravis and its impact on HCG27 regulation. | PLoS One | 2026 | https://conductscience.org/library/papers/42776983 | PubMed |
| 42694599 | The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics. | Front Immunol | 2026 | https://conductscience.org/library/papers/42694599 | PubMed |
| 42598382 | Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database. | Front Neurol | 2026 | https://conductscience.org/library/papers/42598382 | PubMed |
| 42589271 | Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589271 | PubMed |
| 41769309 | Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series. | Ther Adv Neurol Disord | 2026 | https://conductscience.org/library/papers/41769309 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| FCGRT | 2217 | PubTator's text mining | https://conductscience.org/library/genes/2217 | NCBI Gene |
| IL17A | 3605 | PubTator's text mining | https://conductscience.org/library/genes/3605 | NCBI Gene |
| IL23A | 51561 | PubTator's text mining | https://conductscience.org/library/genes/51561 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| LRP4 | 4038 | PubTator's text mining | https://conductscience.org/library/genes/4038 | NCBI Gene |
| MUSK | 4593 | PubTator's text mining | https://conductscience.org/library/genes/4593 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41008338
GET https://conductscience.org/api/papers/v1/41008338/references?page=2